Global Neuraminidase Inhibitors Market – Industry Trends and Forecast to 2029

Global Neuraminidase Inhibitors Market, By Indication (Influenza Virus Type A, Influenza Virus Type B, Others), Product (Zanamivir, Oseltamivir, Peramivir, Laninamivir, Other), Route of Administration (Oral, Inhalation, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Neuraminidase Inhibitors Market Analysis and Size

The global neuraminidase inhibitors market is expected to witness significant growth during the forecast period. Growing cases of influenza viruses A and B infection drives the neuraminidase inhibitors market.  The major market players in the neuraminidase inhibitors market are focusing on launching new drugs in the market, which is expected to grow in the market in the forecast period. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global neuraminidase inhibitors market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Neuraminidase inhibitors are the type of antiviral drugs that are active against influenza viruses type A & B. These inhibitors act by binding to the concerned region of neuraminidase protein present on the viral surface to constrain viral replication, penetration and prevent new host cells from being infected. The neuraminidase inhibitors are recommended for the treatment of the symptoms after the onset of symptoms post forty eight hours.

Neuraminidase Inhibitors Market Scope and Segmentation

Global Neuraminidase Inhibitors Market Dynamics

Drivers

• Rare Resistance Development

The inhibitors provide rare resistance to influenza, thus it is used in good quantity to achieve better results. The whole process of resistance development is important to treat influenza. This is anticipated to increase the demand for neuraminidase inhibitors, which will also increase the market growth. Thus, it boosts the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Technological Development

Several technological developments in the field are constantly improving for the patients' better improvement. Major market players primarily focus on upgrading the drugs, which works as an opportunity for the market to grow. In addition to this, improving treatment, better equipment for disease detection, and hospital facilities are expected to boost the market demand. Thus, all these factors enhance the market expansion.

• Increasing Demand for Retail Pharmacies

The rise in the number of renal drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Side Effects of Renal Drugs

The side effects associated with these inhibitors could curb the growth of the global renal drugs market over a forecast period. Effects such as vomiting, nausea, pain, and several others, can hamper the market growth.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth.

This global neuraminidase inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global neuraminidase inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Neuraminidase Inhibitors Market            

COVID-19 had a major impact on the neuraminidase inhibitors market; even in the post pandemic situation, the market is expected to grow. It is seen that the levels of N-acetylneuraminic acid and neuraminidase were found to be high in the hospitalized COVID-19 patients, suggesting increasing desialylation in COVID-19 patients.

Global Neuraminidase Inhibitors Market Scope

The global neuraminidase inhibitors market is segmented on the basis of indication, product, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Influenza Virus Type A
• Influenza Virus Type B
• Others

Product

• Zanamivir
• Oseltamivir
• Peramivir
• Laninamivir
• Other

Route of Administration

• Oral
• Inhalation
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Neuraminidase Inhibitors Market Regional Analysis/Insights

The global neuraminidase inhibitors market is analysed and market size insights and trends are provided by indication, product, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global neuraminidase inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a highest growth for global neuraminidase inhibitors market throughout the forecasted period due to high prevalence of influenza virus & increased population and rapidly improving health care infrastructure in the region.

North America dominates the market due to increased high prevalence of influenza flu.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Neuraminidase Inhibitors Market Share Analysis

The global neuraminidase inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global neuraminidase inhibitors market.

Key players operating in the global neuraminidase inhibitors market include:

• Pfizer Inc (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel)
• Sun Pharmaceutical Industries Ltd (India)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Lupin (India)
• Cipla Inc (India)
• Aurobindo Pharma (India)
• Fresenius SE & Co. KGaA (Germany)
• Sanofi (France)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• BIOCRYST PHARMACEUTICALS, INC. (U.S.)
• NATCO Pharma Limited (India)